AbbVie, Evolus, and Medytox Announce Resolution of Intellectual Property Litigation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Evolus (EOLS) PT Raised to $25 at Stifel Following Settlement
February 19, 2021 1:28 PM ESTStifel analyst Annabel Samimy raised the price target on Evolus (NASDAQ: EOLS) to $25.00 (from $11.00) while maintaining a Buy rating following settlement.
Settlement Is a Win For All; EOLS Shares Released from Overhang... More